Insulin companies commit to CMS program that caps Medicare out-of-pocket insulin costs

The three major U.S. insulin suppliers, Eli Lilly, Novo Nordisk and Sanofi, said they will participate in a program CMS announced Wednesday that will cap out-of-pocket insulin costs for Medicare beneficiaries.

CMS will allow enhanced Medicare Part D plans to provide insulin at a maximum $35 co-pay per month. Medicare beneficiaries who enroll in a plan that participates in the plan will save an average of $446 per year in out-of-pocket costs, CMS said. ...